237 related articles for article (PubMed ID: 25123042)
1. Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future.
Li Y; Song L; Gong Y; He B
Biomark Med; 2014; 8(5):755-69. PubMed ID: 25123042
[TBL] [Abstract][Full Text] [Related]
2. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
Song L; Li Y
Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
Song L; Yu H; Jia J; Li Y
Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
5. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening.
Wu D; Zhou G; Jin P; Zhu J; Li S; Wu Q; Wang G; Sheng J; Wang J; Song L; Han X; Qian J
J Mol Diagn; 2016 Jul; 18(4):535-45. PubMed ID: 27133379
[TBL] [Abstract][Full Text] [Related]
6. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening.
Song L; Peng X; Li Y; Xiao W; Jia J; Dong C; Gong Y; Zhou G; Han X
Epigenomics; 2017 May; 9(5):599-610. PubMed ID: 28470092
[TBL] [Abstract][Full Text] [Related]
7. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
Payne SR
Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
[TBL] [Abstract][Full Text] [Related]
9. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population.
Lima AB; Dos Reis MB; Matsushita M; Dos Reis MT; de Oliveira MA; Reis RM; Guimarães DP
Cancer Med; 2023 Aug; 12(15):15854-15867. PubMed ID: 37338022
[TBL] [Abstract][Full Text] [Related]
10. The role of
Sun J; Fei F; Zhang M; Li Y; Zhang X; Zhu S; Zhang S
BMC Cancer; 2019 May; 19(1):450. PubMed ID: 31088406
[TBL] [Abstract][Full Text] [Related]
11. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.
Zhao G; Li H; Yang Z; Wang Z; Xu M; Xiong S; Li S; Wu X; Liu X; Wang Z; Zhu Y; Ma Y; Fei S; Zheng M
Cancer Med; 2019 Sep; 8(12):5619-5628. PubMed ID: 31407497
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.
Sun G; Meng J; Duan H; Zhang D; Tang Y
Pathol Oncol Res; 2019 Oct; 25(4):1525-1534. PubMed ID: 30488278
[TBL] [Abstract][Full Text] [Related]
13. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
[TBL] [Abstract][Full Text] [Related]
14. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis.
Song L; Jia J; Peng X; Xiao W; Li Y
Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563
[TBL] [Abstract][Full Text] [Related]
15. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
16. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
17. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
[TBL] [Abstract][Full Text] [Related]
18. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
19.
Semaan A; van Ellen A; Meller S; Bergheim D; Branchi V; Lingohr P; Goltz D; Kalff JC; Kristiansen G; Matthaei H; Pantelis D; Dietrich D
Clin Epigenetics; 2016; 8():100. PubMed ID: 27660666
[TBL] [Abstract][Full Text] [Related]
20. Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer.
Shavali M; Moradi A; Tahmaseb M; Mohammadian K; Ganji SM
BMC Med Genomics; 2024 Apr; 17(1):117. PubMed ID: 38689296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
